ScienceCrossing the borders of innovationBasing clinical trials on sound mechanistic and scientific rationale.Combating Pan-Cancer with PrecisionCombating Pan-Cancer with PrecisionSaving Lives of Patients Who Exhausted Treatment Options and Improving Clinical BenefitsPatient no boxCancer Patients are fighting for their lives...we will fight with themImagining a world without cancer. Apollomics是一家致力于发现和开发肿瘤组合疗法的创新型生物制药公司。 管道 科学 活动 我们的愿景 成为癌症患者新型药物开发的全球领导者。 学到更多 最近的新闻 November 16, 2023 Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer November 15, 2022 Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor Aberrations 更多新闻
